Lenacapavir and Fostemsavir in Multidrug-Resistant HIV-1: Real-World Data

A single-center French retrospective cohort documents virological outcomes, resistance emergence, and therapeutic drug monitoring for two novel antiretrovirals in heavily treatment-experienced people with HIV-1, reinforcing adherence as the dominant determinant of success.

lenacapavirfostemsavirtemsavircabotegravircapsid inhibitorattachment inhibitormultidrug-resistant HIV-1heavily treatment-experiencedantiretroviral resistancetherapeutic drug monitoringreal-world evidenceretrospective cohortHIV Infectious Disease / Antimicrobials

Background Information

New HIV drugs show promise for resistant cases in France.

Lenacapavir and fostemsavir are new treatment options for managing multidrug-resistant HIV-1, offering hope in complex cases where traditional therapies fail. In a cohort of 21 patients, 82% of those previously viremic achieved viral suppression, with poor adherence linked to treatment failure and resistance. Real-world data confirm the effectiveness and safety of lenacapavir and fostemsavir for multidrug-resistant HIV-1, highlighting the importance of adherence in achieving optimal outcomes. Lenacapavir and fostemsavir are effective options for multidrug-resistant HIV-1 with adherence support crucial to treatment success.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M

Citation: Boujamline S, Boschi C, Bes-Barlandier H, et al. Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. Journal of medical virology. 2026;98(9):e71149. doi:10.1002/jmv.71149

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →